The method of treatment of subclinical forms of genital herpes infection in women |
|
IPC classes for russian patent The method of treatment of subclinical forms of genital herpes infection in women (RU 2191576):
 Antiviral agent / 2190402
The invention relates to the field of medicine and is suitable for the treatment and prevention of viral diseases
 Method of treatment of anogenital herpes-viral infection / 2189793
The invention relates to medicine, namely to dermatology, and can be used in the treatment of herpes virus infection
 The method of obtaining derivatives of imidazole / 2188821
The invention relates to an improved process for the preparation of compounds of formula III
 < / BR>where R1is hydrogen or heteroaromatic, R2is a group selected from CH2-O-aralkyl, CH2OCO-alkyl, CH2ОСОNН2CH2ОСОРh, CH2LLC-alkyl; R3- C3-alkyl; R4- dichlorophenyl, including interaction of the compounds of formula I  < / BR>where R1, R2and R3such as defined above, with a compound of formula II: R4-S-Hal, where R4like is definitely above and Hal represents halogen, in the presence of a base  N-substituted derivatives of 5-oxigenobaroterapia acid / 2188196
The invention relates to medicine, more specifically to pharmacology, specifically to synthetic biologically active compounds of the heterocyclic series
 Imidazole derivatives and pharmaceutically acceptable composition / 2188194
The invention relates to imidazole derivative of General formula I, where n=0 or 1, R1is hydrogen, alkyl, R2is hydrogen or R2and R3form a double bond, R3is hydrogen, alkyl, R4is hydrogen, alkyl, hydroxy-group, alkoxy, R5is hydrogen or alkyl, or R4and R5form a carboxyl group, R6, R7, R8is hydrogen, alkyl, hydroxy-group, alkoxy, hydroxyalkyl, halogen, X-CHR9-(CHR10)m-, m = 0 or 1, R9and R10is hydrogen or alkyl
 Derivatives of 5'-h-phosphonate 3'-azido-3'-deoxythymidine and pharmaceutical compositions based on them / 2187509
The invention relates to new antiviral derived 5'-H-phosphonate 3'-azido 3'-deoxythymidine General formula I
 < / BR>where R represents isopropyl, neopentyl or cyclohexyl, containing pharmaceutical compositions  Remedy / 2187332
The invention relates to medicine and the pharmaceutical industry and relates to dosage forms containing recombinant interferon
 Drug / 2187331
The invention relates to medicine and the pharmaceutical industry and relates to encapsulated or tableted form of pharmaceutical preparations containing recombinant interferon
 Antiviral agent / 2187330
The invention relates to medicine and the pharmaceutical industry and relates to formulations for the prevention and treatment of viral diseases, containing recombinant interferon
 Antiviral, antimicrobial and protivokariosnoe tool / 2187328
The invention relates to medicine and the pharmaceutical industry and relates to dosage forms containing cytokine
 Inhalation drug, acute asphyxia in bronchial asthma and bronchospasm / 2191024
The invention relates to medicine, in particular for inhalation preparations, with the ability to resolve the obstruction (narrowing of the bronchi) by removing the first and second phase of allergic airway inflammation and spasm of the smooth muscles of the bronchi
 The method of detoxification / 2190412
The invention relates to medicine and can be used for detoxification of the body
A strain of bacillus firmus used for the manufacture of probiotic drug intended for the prevention and treatment of bacterial enteric infections of young farm animals / 2190016
The invention relates to veterinary Microbiology, may be used for the manufacture of probiotic preparation with preventive and curative action of intestinal infections of young farm animals caused by pathogenic enterobacteria of the genus Proteus, Morganella, Providencia, Yersinia and other intestinal infections occurring with the participation of the mentioned bacteria
 Lactobacillus brevis ba-13, used for the preparation of probiotic preparations and food / 2190015
The invention relates to medicine, namely to manufacture drugs-probiotics
 The use of the extract of non-photosynthetic filamentous bacteria-containing composition / 2188029
The invention relates to the field of medicine and for the application of at least one extract of non-photosynthetic filamentous bacteria as an antagonist of substance P for the treatment of diseases associated with excessive synthesis and/or release of substance P
 Method of cooking basics for medicinal and cosmetic preparations / 2187994
The invention relates to pharmaceutical and cosmetic industries and can be used in the preparation of the basis for medicinal and cosmetic preparations
 The way to determine the antagonistic activity of probiotics / 2187801
The invention relates to medicine, in particular to Microbiology
 Treatment of chronic gastritis and peptic ulcer of the duodenum / 2187318
The invention relates to medicine, in particular to therapy, and can be used for the treatment of chronic gastritis and peptic ulcer of the duodenum
 Method for the treatment and prevention of fish diseases / 2186576
The invention relates to the field of biotechnology and veterinary medicine
 New drug lactic acid bacteria with properties of biological treatment (options) / 2186575
The invention relates to biotechnology and medicine
 The treatment of seizures / 2191017
The invention relates to medicine, specifically to the means of the treatment of seizures predominantly toxic etiology on the basis of anticonvulsant class of benzodiazepines sibazona
|
(57) Abstract: The invention relates to medicine, namely, venereology, and is intended for outpatient treatment of patients with subclinical genital herpes infection (GVI). The use of the antiviral drug valtrex immunomodulatory agent neovir and drug affecting the microflora of the genitourinary tract - Azilect in certain doses and modes. The method allows to stop warusawithana from the urinary tract in 90,5% of cases, to prevent the possibility of recurrence. table 1. The invention relates to medicine, namely to venereology, intended for outpatient treatment of patients with subclinical genital herpes infection (GVI). There is a method of treatment of patients with subclinical (asymptomatic) form of genital GVI with the use of combination therapy (antiviral and immunomodulatory drug) (Batkaev E. A., Lipova E. C. Treatment of genital herpes and urogenital chlamydiosis. Moscow, 1999). As antivirals use different virustatic (acyclovir, valtrex, alpizarin, methisazone, mirasol and others). As immune Postdam of this method is the low percentage of therapeutic effect (70%), in 30% of patients continued warusawithana from the urinary tract, i.e., they remain sources of infection and they saved the probability of a transition of this form of the disease in the manifest. The leading role in the pathogenesis of herpesvirus infection belongs to the interferon immune system, as demonstrated by a number of authors (Gumiho P. A. , 1990, Quratulain K. N., 1991, Holden A. A., 1995, Dry, I., Vanko L. C., fists Century. And., 1997). Known drug neovir. The drug causes parenteral quick education in the body of high titers of endogenous interferon. As a result, the cells formed a state of resistance to viruses, and induced immune responses aimed at the destruction of virus infected cells. Known drug valacyclovir (valtrex), intended for oral therapy of herpes infections. Getting in the cage, he has a specific inhibitory effect on the replication of herpes virus. Known drug Azilect. Azilect is a microbial mass of live acidophilus lactobacilli, which have high antagonistic activity in the preparations for violations bacteriocins genitals. The aim of the invention is to increase therapeutic efficacy, discontinuation of warusawithana in patients with subclinical genital Guinea, as well as reducing the likelihood of possible occurrence of relapses in the form of rashes in patients with this form of the disease. The objective is achieved by a more pronounced therapeutic effect in complex use of the antiviral drug valtrex, immunomodulating drug neovia and drug affecting the microflora of the genitourinary tract - Azilect. Patients with subclinical genital GVI prescribe valtrex 0.5 g 2 times a day for 10 days, the dose rate of 10 g, at the same time appoint neovir at a dose of 250 mg intramuscularly 10 injection, the interval between injections 48 hours (immediately before injection, the drug is diluted with 1.5 ml of 0.5% solution of novocaine). After administration of valtrex prescribed Azilect in the form of vaginal suppositories by 5 doses daily at night for 10 days. To destination therapy in patients to assess the ecological community sexual tract determine the authors estimated the effect activity of the vagina ("Method of rapid diagnosis of the inflammatory process of female genitalia"house of culture on blood agar). Is the table with their own data dynamics lysozyme activity and pH of the vagina. The results of the comparative analysis before and after treatment indicate that under the influence of treatment of vaginal pH is normalized with increasing lysozyme activity. The use of the proposed method is illustrated by the following examples. Example 1. Patient P. , 25 years. Diagnosis: Genital herpes, subclinical course. Worried about burning, discomfort in the genital area, moderately expressed in serous vaginal discharge for 2 years. Gynecological examination at the place of residence of bacterial and fungal infections were not identified, however, the patient had regular courses of local therapy with the use of vaginal suppositories with anti-fungal and antibacterial effect. The positive effect of treatment was not achieved. The clinical-laboratory examination in Arnie DV and in the urogenital tract was detected herpes simplex virus type 2, of vaginal pH to 5.0, the authors estimated the effect activity of the vagina - negative flora sexual tract was presented by streptobacilli, hemolytic Streptococcus, non-haemolytic with etani with neovia at a dose of 250 mg, ten injections with an interval between injections 48 hours. After receiving the valtrex was appointed Azilect in the form of vaginal suppositories by 5 doses daily at night for 10 days. On the background of therapy subjective feelings were relieved by the 4th day of treatment. The control tests herpes simplex virus type 2 was not detected in the genital tract, the authors estimated the effect activity of the vagina is 6 mm, the pH of the vagina to 4.0, total bacterial count 105(lactobacilli, G+ coli, Staphylococcus non-haemolytic). During 1 year of observation of the patient, the complaint was not pursued, and laboratory indicators at the same level. Example 2. Patient P. , 29 years. Diagnosis: Genital herpes, subclinical course. Worried about burning in the genital area, serous discharge from the vagina for 3 years. Gynecological examination at the place of residence in General, the analysis of a smear has repeatedly determined the increase in the number of cells to 40-80, but bacterial and fungal infections are identified. The patient had regular courses total antibiotic therapy and local treatment with vaginal suppositories with anti-fungal and antibacterial effect. Put the tract was detected herpes simplex virus type 2, of vaginal pH to 5.0, the authors estimated the effect activity of the vagina - negative flora sexual tract was presented by streptobacilli, non-haemolytic Staphylococcus, Streptococcus, total bacterial count 106. The patient was assigned valtrex 0.5 g 2 times a day for 10 days in combination with neovia at a dose of 250 mg intramuscularly, ten injections with an interval between injections 48 hours. After receiving the valtrex was appointed Azilect in the form of vaginal suppositories by 5 doses daily at night for 10 days. On the background of therapy subjective feelings were stopped. The control tests herpes simplex virus type 2 was not detected in the genital tract, the authors estimated the effect activity of the vagina - 5 mm, of vaginal pH to 4.0, total bacterial count 105(lactobacilli, G+ Bacillus, Corynebacterium). Over 1.5 years of observation of the patient, the complaint was not pursued, and laboratory indicators at the same level. Proposed method and applying to monitor the effectiveness of these methods, Arnie DV and treated 21 patients with subclinical genital Guinea, a control group of 16 people. During treatment, the side effects were not identified. In 100% of patients with subclinical genital herpes n the l detected in the genital tract in routine analyses in 90,5% (19 people). To assess the condition of microflora of the genital tract and the impact of the proposed treatment method for its correction (to stop warusawithana from the urinary tract) patients determine before treatment and after its completion, the authors estimated the effect activity of the vagina (using the above method), pH of the vagina, the total microbial number and types of microorganisms (sowing detachable genital tract on blood agar). Before treatment, patients were dominated by the shift of vaginal pH in an alkaline medium under negative lysozyme activity vagina, total bacterial count 104-105in 47.6% of patients, 106in 33.3%, 107- 19,1%, in the flora was dominated by streptobacilli, hemolytic Streptococcus and Staphylococcus, non-haemolytic Streptococcus at low concentrations of lactobacilli, which is indicative of impaired ecosystem sexual tract. After therapy in 100% of patients showed normalization of vaginal pH (3,8-4,2), the authors estimated the effect activity of the vagina up to 2 mm in 23.8% of patients, from 2 to 4 mm - 47,6%, more than 4 mm to 19%. Total bacterial count remained in the predominant value of 104-105(52.4% of patients), but in the genital tract were not found hemolytic Streptococcus and Staphylococcus, spacesubcommittee forms of genital GVI allows you to stop warusawithana from the urinary tract in 90,5%, which is more pronounced than when using the known method. The results are shown in the table. The method of treatment of subclinical forms of genital herpes infection in women, including the use of antiviral and immunomodulatory drugs, characterized in that patients prescribed valtrex 0.5 g 2 times a day, a course of 10 days, at the same time appoint neovir 250 mg intramuscularly, 10 injections, the interval between injections 48 h after administration of valtrex prescribed Azilect in the form of vaginal suppositories by 5 doses daily at night for 10 days.
|